Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy

Nils-Petter Rudqvist; Manushak Avagyan; Dhan Chand

doi:10.1080/2162402X.2023.2275333

Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy

Oncoimmunology. 2023 Nov 5;12(1):2275333. doi: 10.1080/2162402X.2023.2275333. eCollection 2023.

Authors

Nils-Petter Rudqvist¹, Manushak Avagyan¹, Dhan Chand¹

Affiliation

¹ Agenus Inc, Lexington, MA, USA.

Abstract

Radiation therapy and anti-CTLA-4 combination therapy can induce meaningful responses in some patients. Adding CD40 may provide additional benefit. Next-generation anti-CTLA-4 antibodies, such as botensilimab, are showing promise in clinical trials. Combining botensilimab with RT and/or CD40 agonist may offer additional benefits for challenging tumor types.

Keywords: CTLA-4 blockade; Clinical trials; immune checkpoint blockade; next generation immunotherapy; radiation therapy.

MeSH terms

CTLA-4 Antigen
Combined Modality Therapy
Humans
Immunotherapy*
Neoplasms* / drug therapy

Substances

CTLA-4 Antigen

Grants and funding

The author(s) reported there is no funding associated with the work featured in this article.